C4 Therapeutics (CCCC) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 107.3% versus a gain of 24.8%. Over five years, OBIO leads with a -42.5% price change compared with -93.6% for CCCC. Orchestra BioMed is the larger company by market cap ($341.4 million vs $336.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | OBIO |
|---|---|---|
| Share price | $2.74 | $5.68 |
| Market cap | $336.47M | $341.40M |
| 1-day change | -3.01% | +0.35% |
| YTD return | +47.64% | +36.39% |
| 1-year return | +24.78% | +107.33% |
| 5-year return | -93.57% | -42.54% |
| EPS (TTM) | $-0.91 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $6.50 |
| 52-week low | $1.69 | $2.78 |
| Distance from 52-week high | -47.10% | -12.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +387.39% | +118.84% |
| Average volume | 2.38M | 299.24K |
| Shares outstanding | 123.03M | 60.11M |
| Employees | 104 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed CCCC by 82.5 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
CCCC vs OBIO FAQ
Which is bigger, C4 Therapeutics or Orchestra BioMed?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $341.40M compared with $336.47M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or OBIO?
OBIO returned +107.33% over the past 12 months, compared with +24.78% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Orchestra BioMed in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for C4 Therapeutics and Medicinal Chemicals and Botanical Products for Orchestra BioMed.